IGF-1 LR3 Research: IGF-1 Receptor Activation and Myocyte Cell Model Studies
The content, articles and product information provided on this website are strictly educational and informational. They are intended to be used for in vitro research only. “In vitro” is a Latin phrase, “in glass,” that refers to research that is conducted outside of a living organism. Note, these products are not pharmaceuticals or medicines and have not been approved by the FDA for the diagnosis, treatment or prevention of any illnesses or disorders. These products are legally prohibited from human or animal consumption.
IGF-1 LR3 Research Overview
IGF-1 LR3 is a 83-amino acid synthetic analogue of IGF-1 incorporating an N-terminal 13-amino acid extension and Glu3-to-Arg3 substitution. These modifications reduce IGFBP binding affinity by approximately 1000-fold while maintaining IGF-1R binding capacity, extending the biological half-life in cell culture research models compared to native IGF-1. The structural modifications create a valuable research tool for investigating IGF-1 receptor pharmacology without interference from insulin-like growth factor binding proteins.
IGF-1 Receptor Binding Research
Binding Affinity Characterization
IGF-1 LR3 binds IGF-1R with affinity approximately 2-3 times higher than native IGF-1 in competitive radioligand assays using [125I]-IGF-1 as reference ligand. Reduced IGFBP binding enables more direct receptor-ligand interactions in cell-based assays. Scatchard analysis demonstrates single-site binding kinetics with Kd values ranging from 0.8-1.2 nM across various cell lines expressing endogenous IGF-1R.
Cross-Reactivity Studies
Receptor selectivity assays reveal minimal cross-reactivity with insulin receptors at concentrations below 100 nM. IGF-1 LR3 shows approximately 10-fold selectivity for IGF-1R over insulin receptor subtypes in transfected cell models. This selectivity profile makes it particularly useful for isolating IGF-1R-specific signalling pathways in experimental systems.
Cellular Signalling Pathways
PI3K/Akt Pathway Activation
IGF-1 LR3 treatment activates phosphoinositide 3-kinase signalling cascades with EC50 values typically ranging from 2-5 nM in myocyte cell models. Akt phosphorylation at Ser473 and Thr308 sites occurs within 5-15 minutes of exposure, demonstrating rapid signal transduction. Time-course studies show sustained Akt activation lasting 2-4 hours in serum-free culture conditions.
MAPK Signalling Responses
Extracellular signal-regulated kinase phosphorylation follows biphasic kinetics with initial peak activation at 10-30 minutes post-treatment. IGF-1 LR3 demonstrates potent ERK1/2 activation with maximal responses at concentrations of 5-10 nM. The sustained signalling profile differs from native IGF-1, likely due to reduced IGFBP sequestration in culture media.
Cell Model Applications
Primary Myocyte Studies
Primary skeletal myocyte cultures provide relevant models for studying IGF-1 LR3 receptor pharmacology. Dose-response curves in differentiated myotubes show maximal receptor activation at 10-20 nM concentrations. Cell viability assays confirm biocompatibility across concentration ranges from 0.1-100 nM over 72-hour exposure periods.
Immortalized Cell Line Research
C2C12 myoblast cell lines offer reproducible models for IGF-1R signalling studies. IGF-1 LR3 promotes differentiation marker expression with similar potency to native IGF-1 but with extended duration of response. Quantitative PCR analysis reveals upregulation of myogenic transcription factors following 24-48 hour treatments.
Enzyme Kinetics and Metabolic Assays
Protein Synthesis Measurements
Puromycin incorporation assays demonstrate IGF-1 LR3-mediated protein synthesis enhancement with EC50 values of 3-7 nM in myocyte models. The extended half-life allows for sustained anabolic signalling without repeated dosing in culture systems. Time-course studies reveal maximal incorporation rates at 4-6 hours post-treatment.
Glucose Uptake Mechanisms
2-Deoxyglucose uptake assays show IGF-1 LR3 stimulates glucose transporter translocation with potency similar to insulin at supraphysiological concentrations. GLUT4 translocation occurs through IGF-1R-mediated PI3K activation, confirming receptor-specific mechanisms. Kinetic analysis reveals Vmax increases without significant Km changes in transporter function.
Stability and Storage Considerations
IGF-1 LR3 demonstrates enhanced stability compared to native IGF-1 in standard culture media. Bioactivity remains >90% after 48 hours at 37°C in serum-containing media, compared to <20% for native IGF-1 under identical conditions. This stability profile enables extended experimental protocols without frequent media changes.
Research Summary
IGF-1 LR3 represents a valuable pharmacological tool for investigating IGF-1 receptor signalling pathways in vitro. Its enhanced binding affinity, reduced IGFBP interactions, and extended stability make it particularly suitable for cell-based assays requiring sustained receptor activation. The compound demonstrates robust signalling through PI3K/Akt and MAPK pathways with well-characterized dose-response relationships in multiple cell model systems. These properties support its continued use in mechanistic studies of IGF-1 receptor pharmacology and downstream signalling cascades.
All content is intended for in vitro laboratory research purposes only. Not for human or animal consumption. Not intended to diagnose, treat, cure, or prevent any condition.
